Best Peptides for Biohacking Inflammation & Anti-Aging

Written by: Ellie Pranckevicius, FNP-BC, Aesthetic Nurse Practitioner & Aesthetic Injector | Facial Restoration & Regenerative Injectable Specialist, Mirror Plastic Surgery | Last updated: August 6, 2026

Key Takeaways for Peptide Therapy at Mirror Plastic Surgery

• Three primary peptide categories target inflammation, weight loss, and visible aging. GLP-1 and GLP-3R agonists support metabolic fat loss. BPC-157 and KPV address systemic and gut inflammation. GHK-Cu with CJC-1295/Ipamorelin focuses on collagen renewal and age-related changes.
• GLP-1 receptor agonists such as Tirzepatide and Semaglutide have the strongest clinical evidence for visceral fat reduction, with 15–22.5% mean weight loss in Phase III trials.¹
• BPC-157, TB-500, and KPV work on different inflammatory pathways, with relief timelines ranging from a few days to several weeks depending on the condition.
• GHK-Cu, CJC-1295/Ipamorelin, and NAD+ support visible anti-aging by increasing collagen, stimulating growth hormone, and improving mitochondrial function.
• Medical supervision and lab-guided personalization are essential for safe, effective peptide therapy. Schedule your consultation to build a protocol tailored to your biology.

Evidence Snapshot: Peptides Matched to Your Goals

This table separates FDA-approved GLP-1 receptor agonists from experimental research peptides across four attributes. Dosing ranges and timelines differ too much for a single scale, so those details appear in the goal-specific sections that follow.

Peptide	Primary Goal	Regulatory Status (U.S.)	Evidence Tier
Tirzepatide (GIP/GLP-1 dual agonist)	Weight loss, metabolic health	FDA-approved (Mounjaro/Zepbound)	Phase III RCT data, highest clinical evidence
Semaglutide (GLP-1 agonist)	Weight loss, glycemic control	FDA-approved (Ozempic/Wegovy)	Phase III RCT data, highest clinical evidence
GLP-3R Compounding	Weight loss, insulin resistance, cardiovascular risk	Compounded, not independently FDA-approved	Emerging, early clinical and observational data
BPC-157	Systemic inflammation, tissue repair	Not FDA-approved, research compound	Preclinical and early human data
TB-500 (Thymosin Beta-4)	Soft tissue inflammation, wound healing	Not FDA-approved, research compound	Preclinical and early human data
KPV	Gut inflammation, IBD risk reduction	Not FDA-approved, research compound	Preclinical and early human data
GHK-Cu (Copper Peptide)	Collagen/elastin production, skin aging	GHK-Cu is not FDA-approved as a drug and is treated as a research compound for injectable or other non-cosmetic uses, though it has long been an established OTC topical cosmetic ingredient.	In vitro, preclinical, and cosmetic clinical data
CJC-1295 + Ipamorelin	Growth hormone stimulation, body composition, anti-aging	Not FDA-approved, research compound	Preclinical and early human data
NAD+	Cellular energy, mitochondrial anti-aging	Not FDA-approved as a drug, supplement status varies	Preclinical and early human data

Peptides for Inflammation: Systemic and Gut-Focused Options

Peptides for inflammation fall into two main groups, systemic musculoskeletal support and gut-localized support. Each group targets different tissues and pathways.

For systemic inflammation in muscles, tendons, ligaments, and joints, BPC-157 (Body Protective Compound 157) is the most studied experimental option. Preclinical data show faster tissue repair and lower levels of pro-inflammatory cytokines. TB-500 (Thymosin Beta-4) complements BPC-157 by focusing on soft tissue inflammation and wound repair at the cellular level, promoting actin polymerization and new blood vessel growth. Mirror Plastic Surgery’s “Glow Stack” combines GHK-Cu, BPC-157, and TB-500 to address systemic inflammation while also supporting collagen.

For gut-localized inflammation, KPV, a tripeptide fragment of alpha-melanocyte-stimulating hormone, acts directly within the gut environment. Early data suggest that KPV may lower inflammatory markers linked to irritable bowel disease and reduce associated colorectal risk factors. Because gut inflammation often drives overall inflammatory burden, KPV frequently becomes part of broader anti-inflammatory plans after lab review of inflammatory markers.

Timelines differ by compound. BPC-157 and TB-500 users in clinical observation settings often report early symptom relief within days to a few weeks.¹ Gut-targeted KPV protocols usually require several weeks of consistent use before measurable microbiome changes appear.¹

Peptides for Belly Fat and Metabolic Health

GLP-1 receptor agonists have the strongest evidence for reducing visceral and subcutaneous fat. Semaglutide (Wegovy) achieved the 15% mean weight reduction noted in the evidence table above, with a large share of that loss coming from visceral fat rather than lean mass.¹ Tirzepatide’s 16.0–22.5% reduction, the highest in the comparison, makes it the most effective approved agent for visceral fat loss so far.¹

Mirror Plastic Surgery offers GLP-3R compounding as a next-generation alternative for metabolic support. GLP-3R formulations are reported to cause fewer gastrointestinal side effects than earlier GLP-1 agents. They also appear less likely to cause lean muscle loss, a documented concern with first-generation GLP-1 therapies, and they address broader metabolic issues such as insulin resistance and cardiovascular risk factors. Because GLP-3R is a compounded formulation rather than an independently FDA-approved drug, safe use requires medical supervision, lab screening of thyroid, liver, kidney, diabetes markers, and hormone panels, and ongoing monitoring.

Sermorelin and Ipamorelin, which release growth hormone, support fat loss indirectly.¹ They stimulate the body’s own growth hormone production, which helps preserve lean muscle and improve body composition over time. Clinicians typically use these as add-ons to primary metabolic protocols instead of as standalone fat-loss agents.

Because metabolic peptide selection depends on your baseline thyroid, liver, kidney, and hormone markers, a lab-guided consultation is the safest way to choose among GLP-3R, GLP-1 agents, and growth hormone-releasing peptides. Book an appointment with Ellie to review your lab panel and determine which metabolic peptide protocol fits your profile.

Peptides That Support a Younger Look

Visible aging reflects declining collagen and elastin production, reduced growth hormone, and mitochondrial slowdown. Different peptide classes target each of these drivers.

GHK-Cu (Copper Peptide) has the strongest support for skin-level anti-aging.¹ In vitro and cosmetic clinical data show that GHK-Cu increases collagen and elastin gene expression, strengthens the skin barrier, and reduces hyperpigmentation, including melasma.¹ It also supports hair follicles and nail matrix health, so it functions as a multi-tissue anti-aging agent. Mirror Plastic Surgery uses GHK-Cu as both a standalone protocol and a core part of the Glow Stack.

CJC-1295 with Ipamorelin increases pulsatile growth hormone release from the pituitary, which then raises IGF-1 levels. Growth hormone decline contributes to skin thinning, reduced muscle tone, and slower cellular repair with age. By restoring a more youthful growth hormone pattern, this combination supports body composition, skin thickness, and recovery capacity at the same time.¹

NAD+ (Nicotinamide Adenine Dinucleotide) targets mitochondrial function. Cellular NAD+ levels fall with age, which harms energy metabolism and DNA repair. Supplementing NAD+, usually through IV or subcutaneous protocols, is associated in early human data with higher cellular energy, better metabolic efficiency, and a subjectively more youthful appearance and vitality.¹

Supervised vs. Unregulated Peptides: Safety and Sourcing

The main risk with peptide use often comes from unregulated sourcing without medical oversight. Many online peptide retailers operate outside pharmaceutical quality-control systems. Their products may contain inaccurate active ingredient levels, unlisted contaminants, or incorrect dosing instructions. Without third-party batch testing, you cannot reliably confirm what is in the vial.

Medical supervision addresses several distinct risk categories that unregulated sourcing cannot by creating a safety framework before, during, and after peptide use:

• Pre-existing condition screening: Certain peptides are contraindicated in people with specific thyroid, liver, kidney, or cancer histories. Lab panels reveal these issues before treatment begins.
• Drug interaction assessment: Beyond static contraindications, peptides can interact with current medications, including immunosuppressants, hormone therapies, and diabetes drugs. A clinician must review the full medication list.
• Accurate dosing: Effective and safe dosing depends on weight, goals, and baseline lab values. Self-dosing without this data raises the risk of under-dosing, which brings no benefit, and over-dosing, which raises the chance of adverse events.
• Quality assurance: Mirror Plastic Surgery uses peptide sources that provide rigorous batch testing for purity, potency, and sterility. Online retailers do not consistently meet this standard.

The gap between a supervised protocol and an unregulated purchase is not a matter of preference. For non-FDA-approved compounds, medical supervision functions as the primary safety system available to the patient.

How Peptide Therapy Works at Mirror Plastic Surgery

Ellie Pranckevicius, FNP-BC, leads the peptide program at Mirror Plastic Surgery. She is a board-certified Family Nurse Practitioner with four years of experience in the Neuroscience ICU at Tampa General Hospital, advanced aesthetics training, and a Master’s in Nursing from the University of South Florida. Her background in both physiology and aesthetics allows her to evaluate systemic health and visible outcomes together.

The process follows a structured concierge model:

1. 30–60-minute consultation: Ellie reviews your medical history, current medications, and specific health and aesthetic goals. For weight loss or inflammatory concerns, she reviews or orders comprehensive lab panels that cover thyroid, liver, kidney, diabetes markers, and hormone levels.
2. Custom peptide stack design: She builds a personalized protocol based on your consultation and lab results. This may involve single peptides or multi-peptide stacks such as the Glow Stack, tailored to your physiology instead of a one-size-fits-all template.
3. Batch-tested sourcing: All peptides come from reputable compounding providers with documented batch testing, which supports purity and accurate dosing.
4. 24/7 concierge support: You receive direct text access to Ellie for questions, dosing guidance, reconstitution instructions with video demonstrations, and refill coordination throughout your protocol.
5. Remote availability: The full process, including consultation, prescription, and shipping, is available across the United States, including Hawaii and Alaska, through telemedicine.

When surgical care is appropriate, Ellie’s work integrates with that of Dr. Akash Chandawarkar, MD, a Harvard-educated physician, Johns Hopkins-trained plastic surgeon, and fellowship-trained aesthetic surgeon at Manhattan Eye Ear & Throat Hospital/Lenox Hill Hospital. This collaboration supports continuity across non-surgical and surgical care.

Important Considerations for Realistic Peptide Results

Several factors shape realistic expectations for peptide therapy outcomes. Understanding these factors helps you interpret your progress over time.

Regulatory status: Aside from FDA-approved GLP-1 agonists such as Semaglutide and Tirzepatide, the peptides in this guide are not FDA-approved drugs. Clinicians use them in supervised clinical and wellness settings based on preclinical and early human data. They can still be effective, but their use makes medical supervision and careful sourcing essential.

Timelines: Initial responses vary by compound and goal. Some patients report relief from inflammatory symptoms within the first week of BPC-157 use.¹ Metabolic changes from GLP-1 or GLP-3R protocols usually become measurable over four to twelve weeks.¹ Collagen-related skin improvements from GHK-Cu protocols often require eight to sixteen weeks of consistent use.¹

Maintenance: Peptide benefits fade after treatment stops.¹ The body gradually returns toward its baseline, similar to what happens when any structured health regimen ends. Maintenance protocols use lower frequency or lower doses to preserve results, and Ellie designs these based on each patient’s response.

Individual variability: Genetics, baseline hormone levels, diet, lifestyle, and other health conditions all influence outcomes. No two patients respond in exactly the same way to a given protocol. This variability is why Mirror Plastic Surgery relies on lab-guided personalization rather than a single standard stack.

Frequently Asked Questions

Are peptides FDA-approved?

GLP-1 receptor agonists such as Semaglutide (Ozempic, Wegovy) and Tirzepatide (Mounjaro, Zepbound) are FDA-approved for specific uses, including type 2 diabetes and chronic weight management. Most peptides used in biohacking and wellness settings, including BPC-157, TB-500, GHK-Cu, KPV, CJC-1295, Ipamorelin, and NAD+, are not FDA-approved as drugs. Clinicians use them in supervised settings based on a growing body of preclinical and early human research. Lack of FDA approval does not mean lack of evidence, but it does mean that quality control, dosing, and safety screening depend on the provider’s sourcing standards and clinical oversight instead of a formal regulatory framework.

What are the risks of using peptides without medical supervision?

Unsupervised peptide use carries two main risks, product quality uncertainty and missing individualized safety screening. Online peptide products do not follow pharmaceutical batch-testing rules, so you cannot verify active ingredient concentration, sterility, or purity. Without a clinical evaluation, there is no screening for contraindications, such as thyroid, liver, kidney, or cancer histories that make certain peptides inappropriate. Incorrect dosing, whether too low to help or high enough to cause side effects, also becomes more likely without lab-guided calibration. Medical supervision supplies the safety structure that the regulatory system does not provide for these compounds.

What happens if I stop taking peptides?

Peptide benefits do not remain permanent after you stop treatment. Your body trends back toward its pre-treatment baseline at a pace that depends on the compound and your physiology. For inflammatory conditions, inflammation usually returns as the peptide’s effect fades.¹ For metabolic peptides such as GLP-1 or GLP-3R agents, weight regain is common after discontinuation without lifestyle changes.¹ For collagen-stimulating peptides such as GHK-Cu, skin improvements slowly diminish as collagen production returns to baseline.¹ Maintenance protocols, which use lower doses or less frequent dosing, help preserve results and are tailored by Ellie to each patient’s response.

Will everyone see the same results from peptide therapy?

Results vary widely between individuals.¹ Genetics, baseline hormone and inflammatory markers, diet, lifestyle, medications, and protocol design all affect outcomes. Two patients on the same GHK-Cu protocol may see very different skin changes based on their starting collagen density and hormonal environment. This variability explains why Mirror Plastic Surgery begins with detailed lab panels and a full medical history instead of a standard protocol. Personalization functions as the mechanism that aligns outcomes with each person’s unique physiology.

Can peptides be used alongside surgical procedures?

Peptides can complement surgical procedures when used under supervision. They may reduce post-operative inflammation and support tissue repair and healing. BPC-157 and TB-500, in particular, appear in post-surgical recovery plans to speed soft tissue healing and lower inflammatory burden during recovery. At Mirror Plastic Surgery, Ellie’s peptide protocols can be coordinated with Dr. Akash Chandawarkar’s surgical care when both are relevant to a patient’s goals, which supports continuity and safety across the full care pathway.

---